natgillin/translations-raw huggingface dataset:
Contents of the pack and other information What Telmisartan Teva Pharma contains
Sadržaj pakiranja i druge informacije Što Telmisartan Teva Pharma sadrži
Telmisartan Teva Pharma may increase the blood pressure lowering effect of other medicines used to treat high blood pressure.
Telmisartan Teva Pharma može povećati učinak snižavanja krvnog tlaka drugih lijekova koji se primjenjuju u liječenju visokog krvnog tlaka.
Arthralgia, pain in extremetis, tendon pain (tendinitis like symptoms)
Artralgija, bol u ekstremitetima, bol tetiva (simptomi poput tendinitisa)
Aluminium-Aluminium blisters : pack sizes of 28, 30 tablets
Aluminij-Aluminij blisteri: veličine pakiranja od 28, 30 tableta.
If you forget to take Telmisartan Teva Pharma
Ako ste zaboravili uzeti Telmisartan Teva Pharma
• Diuretics (‘water tablets'), especially if taken in high doses together with Telmisartan Teva Pharma, may lead to excessive loss of body water and low blood pressure (hypotension).
• Diuretici ('tablete za izmokravanje'), osobito ako se uzimaju visoke doze zajedno s Telmisartanom Teva Pharma,mogu dovesti do prekomjernog gubitka vode u tijelu te niskog krvnog tlaka (hipotenzija).
Such conditions should be corrected before the administration of Telmisartan Teva Pharma.
Takva stanja moraju se korigirati prije primjene Telmisartana Teva Pharma.
Telmisartan Teva Pharma should be used only with caution in patients with mild to moderate hepatic impairment.
Telmisartan Teva Pharma se treba primjenjivati isključivo s oprezom u bolesnika s blagim do umjerenim oštećenjem jetrene funkcije.
Telmisartan Teva Pharma blocks this effect of angiotensin II so that the blood vessels relax, and your blood pressure is lowered.
Telmisartan Teva Pharma blokira učinak angiotenzina II, tako da se krvne žile šire, a krvni tlak snižava.
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Osim ako se produljena terapija antagonistima receptora angiotenzina II ne smatra nužnom, bolesnice koje planiraju trudnoću trebaju prijeći na alternativno antihipertenzivno liječenje s utvrđenim sigurnosnim profilom primjene u trudnoći.
- The other ingredients are microcrystalline cellulose (Avicel PH 102), sodium starch glycolate (Type
Drugi sastojci su: mikrokristalična celuloza (Avicel PH 102), natrijev škroboglikolat (vrste A),
Carefully peel off the top paper layer
Pažljivo odlijepite gornji papirnati sloj 3.
Other conditions with stimulation of the renin-angiotensin-aldosterone system In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8).
U bolesnika čiji vaskularni tonus i funkcija bubrega ovise prvenstveno o djelovanju sustava reninangiotenzin-aldosteron (npr. bolesnici s teškim kongestivnim zatajenjem srca ili osnovnom bolešću bubrega, uključujući stenozu bubrežne arterije) liječenje lijekovima koji utječu na ovaj sustav, kao što je telmisartan, je povezano s akutnom hipotenzijom, hiperazotemijom, oligurijom ili rijetko, akutnim zatajenjem bubrega (vidjeti dio 4.8).
The safety and efficacy of Telmisartan Teva Pharma in children and adolescents aged below 18 years have not been established.
Sigurnost i djelotvornost Telmisartana Teva Pharma u djece i adolescenata u dobi ispod 18 godina nisu ustanovljene.
Telmisartan Teva Pharma is also provided in aluminium-aluminium blister packs of 28 and 30 tablets.
Telmisartan Teva Pharma je također dostupan u aluminij-aluminij blisteru u pakiranju od 28 ili 30
When driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy such as Telmisartan Teva Pharma.
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Prilikom upravljanja vozilima ili strojevima, povremeno može doći do pojave omaglice ili pospanosti, kada se uzima antihipertenzivna terapija poput Telmisartan Teva Pharma.
- if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.
- ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren..
Pharma.
Teva Pharma.
Aluminium-Aluminium blisters : pack sizes of 28 tablets
Aluminij-Aluminij blisteri: veličine pakiranja od 28 tableta.
Tablet
tableta.
Teva Pharma Belgium N.V./S.A.
Luxembourg/Luxemburg Teva Pharma Belgium S.A. Belgien/Belgique
If any of the above applies to you, tell your doctor or pharmacist before taking Telmisartan Teva
Ako se nešto od prethodno navedenog odnosi na Vas, obavijestite liječnika ili ljekarnika prije početka uzimanja Telmisartan Teva Pharma.
These pharmacologically mediated undesirable effects, known from preclinical studies with both angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists, were prevented by oral saline supplementation.
Ove farmakološki posredovane nuspojave, poznate iz pretkliničkih ispitivanja s inhibitorima angiotenzin konvertirajućeg enzima i antagonistima receptora angiotenzina II, bile su spriječene oralnim nadomjeskom soli.
Read the package leaflet for further information
Pročitajte uputu o lijeku za dodatne informacije.
Telmisartan Teva Pharma 20 mg tablets Telmisartan Teva Pharma 40 mg tablets Telmisartan Teva Pharma 80 mg tablets
Telmisartan Teva Pharma 20 mg tablete Telmisartan Teva Pharma 40 mg tablete Telmisartan Teva Pharma 80 mg tablete
If you suffer from a condition called “orthostatic hypotension” (a drop in blood pressure on standing up from a sitting or lying position resulting in dizziness or faintness) your condition may worsen if you take Telmisartan Teva Pharma in combination with:
Ako patite od stanja koje se naziva “ortostatska hipotenzija” (pad krvnog tlaka, tijekom ustajanja iz sjedećeg ili ležećeg položaja, koji dovodi do omaglice ili nesvjestice)
At the beginning of the preventive therapy with Telmisartan Teva Pharma 80 mg, blood pressure should be frequently monitored.
Na početku preventivnog liječenja s Telmisartan Teva Pharmom od 80 mg, krvni tlak treba redovito pratiti.
Exposure to angiotensin II receptor antagonist therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).
Poznato je da izloženost antagonistima receptora angiotenzina II tijekom drugog i trećeg tromjesečja inducira fetotoksičnost u ljudi (smanjenje funkcije bubrega, oligohidramnij, usporena osifikacija kostiju lubanje) i neonatalnu toksičnost (zatajenje bubrega, hipotenzija, hiperkalijemija) (vidjeti dio 5.3.).
Contains sorbitol (E420).
3. POPIS POMOĆNIH TVARI Sadrži sorbitol (E420).
Sepsis including fatal outcome1
Sepsa uključujući smrtni ishod
At the beginning of the preventive therapy with Telmisartan Teva 80 mg, blood pressure should be frequently monitored.
Na početku preventivnog liječenja s Telmisartanom Teva Pharma od 80 mg, krvni tlak treba redovito pratiti.
What you need to know before you take Telmisartan Teva Pharma Do not take Telmisartan Teva Pharma
Što morate znati prije nego počnete uzimati Telmisartan Teva Pharma
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of blisters
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija za blistere
Telmisartan Teva Pharma is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Telmisartan Teva Pharma se ne preporučuje u ranoj trudnoći i ne smije se uzimati ako ste trudni dulje od 3 mjeseca, jer može izazvati teška oštećenja Vašeg djeteta ako se primjenjuje u ovom stadiju (vidjeti dio o trudnoći).
Some side effects can be serious and need immediate medical attention:
Neke nuspojave mogu biti ozbiljne i zahtjevaju hitnu liječničku skrb: Ako Vam se pojave bilo koji od sljedećih simptoma, trebate odmah posjetiti svog liječnika:
Digoxin
• Digoksin
The use of Telmisartan Teva Pharma in children and adolescents up to the age of 18 years is not recommended.
Djeca i adolescenti Primjena Telmisartana Teva Pharma u djece i adolescenata do dobi od 18 godina se ne preporučuje.
Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.90 - 1.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Pokazalo se da je telmisartan slično učinkovit kao i ramipril u prethodno određenom sekundarnom ishodu uključujući kardiovaskularnu smrt, nefatalni infarkt miokarda i nefatalni moždani udar [0,99 (97,5 % CI 0,90 - 1,08), p (neinferiornost) = 0,0004], u primarnom ishodu referentnog ispitivanja HOPE (The Heart Outcomes
Please note that instructions on how to remove the tablet from the blister strip are given on the outer carton of the peelable blisters.
Upute kako izvaditi tabletu iz blistera su naznačene na kutiji blistera sa slojem za odljepljivanje
Telmisartan Teva Pharma is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Telmisartan Teva Pharma se ne preporučuje u ranoj trudnoći te se ne smije uzimati ako ste trudni dulje od 3 mjeseca, jer može izazvati teška oštećenja djeteta ako se primjenjuje nakon trećeg mjeseca trudnoće.
How to take Telmisartan Teva Pharma
Kako uzimati Telmisartan Teva Pharma
In the “Prevention Regimen For Effectively avoiding Second Strokes” (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.00 - 2.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
“Prevention Regimen For Effectively avoiding Second Strokes”) u bolesnika u dobi od 50 godina i starijih, koji su nedavno imali moždani udar, zabilježena je povećana incidencija sepse za telmisartan u usporedbi s placebom, 0,70 % u odnosu na 0,49 % [RR 1,43 (95 % interval pouzdanosti 1,00 - 2,06)].
Telmisartan Teva Pharma contains sodium
Telmisartan Teva Pharma sadrži natrij
Telmisartan Teva Pharma is provided in peelable perforated unit-dose aluminium-aluminium blisters and perforated unit-dose aluminium-aluminium blisters containing 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for each type of blister presentation, although not all pack sizes may be marketed.
Telmisartan Teva Pharma je dostupan u aluminij-aluminij perforiranim blisterima s odvojivim slojem djeljivima na jedinične doze i aluminij-aluminij perforiranim blisterima djeljivima na jedinične doze, svaka vrsta blistera sadrži 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta, iako se na tržištu se ne moraju nalaziti sve veličine pakiranja.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of peelable blisters
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija za blistere s odvojivim slojem
Oral use Read the package leaflet before use.
Prije uporabe pročitajte uputu o lijeku.
This medicine contains 21.4 mg sorbitol in each tablet.
Ovaj lijek sadrži 21,4 mg sorbitola u jednoj tableti.
The other side of the tablet is debossed with the number "7458".
Na drugoj strani tablete utisnut je broj „7458“.
The other side of the tablet is debossed with the number "7460".
Na drugoj strani tablete utisnut je broj „7460“.
This medicine contains 85.6 mg sorbitol in each tablet.
Ovaj lijek sadrži 85,6 mg sorbitola u jednoj tableti.
• manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or
Smanjenje kardiovaskularnog morbiditeta u odraslih osoba s: - manifestnom aterotrombotskom kardiovaskularnom bolešću (anamneza koronarne bolesti srca,
For treatment of high blood pressure the usual dose of Telmisartan Teva Pharma for most patients is 40 mg once a day to control your blood pressure over the 24-hour period.
Za terapiju povišenog krvnog tlaka uobičajena doza Telmisartana Teva Pharma za većinu bolesnika je jedna tableta od 40 mg jedanput na dan za kontrolu Vašeg krvnog tlaka tijekom 24 sata.
The Marketing Authorisation Holder is:
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač Nositelj odobrenja za stavljanje lijeka u promet je:
Diabetic patients treated with insulin or antidiabetics In these patients hypoglycaemia may occur under telmisartan treatment.
U ovih bolesnika hipoglikemija se može pojaviti kod liječenja telmisartanom.
White to off white, oval shaped tablet; one side of the tablet is debossed with the number "93".
Bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete utisnut je broj „93“.
Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin.
Telmisartan ne inhibira angiotenzin konvertirajući enzim (kininaza
This medicine contains 42.8 mg sorbitol in each tablet.
Ovaj lijek sadrži 42,8 mg sorbitola u jednoj tableti.
Pack sizes of 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tablets for peelable perforated blisters.
Veličine pakiranja od 14x1, 28x1, 30x1, 40x1, 56x1, 60x1, 84x1, 90x1, 98x1, 100x1 tableta za perforirane blistere djeljive na jedinične doze.
Volume and/or sodium depletion should be corrected prior to administration of Telmisartan Teva Pharma.
Deplecija volumena i/ili natrija se mora korigirati prije primjene
You should see your doctor immediately if you experience any of the following symptoms:
Obratite se svom liječniku ako imate ili ste ikada imali neko od sljedećih stanja ili bolesti:
Talk to your doctor before taking Telmisartan Teva Pharma: - if you are taking digoxin.
Obratite se svom liječniku prije nego počnete uzimati Telmisartan Teva Pharma:
Pliva Hrvatska d.o.o Tel: + 385 1 37 20 000
Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390
- if you are taking any of the following medicines used to treat high blood pressure: - an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetesrelated kidney problems.
- ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću.
- if you are more than 3 months pregnant (It is also better to avoid Telmisartan Teva Pharma in early pregnancy - see pregnancy section).
Nemojte uzimati Telmisartan Teva Pharma - ako ste alergični na telmisartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). - ako ste dulje od 3 mjeseca trudni (također je bolje izbjegavati Telmisartan Teva Pharma u ranoj trudnoći - vidjeti dio o trudnoći).
Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which have been shown to have an additive blood pressure lowering effect with telmisartan.
Kao alternativa, telmisartan se može primjenjivati u kombinaciji s tiazidnim diureticima, kao što je hidroklorotiazid, za koje se pokazalo da imaju dodatan učinak na snižavanje krvnog tlaka s telmisartanom.
Alternatively, Telmisartan Teva Pharma may be used in combination with diuretics (“water” tablets) such as hydrochlorothiazide which have been shown to have an additive blood pressure lowering effect with Telmisartan Teva Pharma.
Alternativno, Telmisartan Teva Pharma se također može primjenjivati u kombinaciji s diureticima (tablete za mokrenje), kao što je hidroklorotiazid, za koje se pokazalo da imaju dodatan učinak snižavanja krvnog tlaka s Telmisartanom Teva Pharma.
Telmisartan Teva Pharma 40 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93".
Telmisartan Teva Pharma 40 mg tablete su bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete je utisnut broj "93".
H-2100 Gödöllő,
TEVA Pharmaceutical Works Private Limited Company H-2100 Gödöllő,
Package leaflet: Information for the user Telmisartan Teva Pharma 40 mg Tablets
Uputa o lijeku: Informacije za korisnika Telmisartan Teva Pharma 40 mg tablete telmisartan
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience these side effects), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
Sepsa* (često nazvana „trovanje krvi“ je teška infekcija s upalnim odgovorom cijelog organizma što može dovesti do smrtnog ishoda), povećanje određenih bijelih krvnih stanica (eozinofilija), nizak broj krvnih pločica (trombocitopenija), teška alergijska reakcija (anafilaktička reakcija), alergijska reakcija (npr. osip, svrbež, otežano disanje, piskanje, oticanje lica ili nizak krvni tlak), niske razine šećera u krvi (u bolesnika sa šećernom bolesti), osjećaj tjeskobe, izrazitapospanost, oštećen vid, ubrzani otkucaji srca (tahikardija), suha usta, nadražaj želuca, poremećaj osjeta okusa (disgeuzija), abnormalna funkcija jetre(vjerojatnost da će iskusiti ovu nuspojavu, veća je za bolesnike iz Japana)**, brzo oticanje kože i sluznice koji mogu dovesti do smrtnog ishoda (angioedem također sa smrtnim ishodom), ekcem (poremećaj kože), crvenilo kože, koprivnjača (urtikarija), težak osip od lijeka, bol u zglobovima (artralgija), bol u udovima, bol tetiva, simptomi nalik gripi, snižen hemoglobin (krvni protein), povišena razina mokraćne kiseline, povišeni jetreni enzimi ili kreatin fosfokinaza u krvi.
• If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Telmisartan Teva Pharma” and “Warnings and precautions”).
“Nemojte uzimati Telmisartan Teva Pharma” i “Upozorenja i mjere opreza”).
Package leaflet: Information for the user Telmisartan Teva Pharma 80 mg Tablets
Uputa o lijeku: Informacije za korisnika Telmisartan Teva Pharma 80 mg tablete telmisartan
There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).
Dvostruka blokada renin-angiotenzin-aldosteronskog sustava (RAAS) Postoje dokazi da istodobna primjena ACE inhibitora, blokatora angiotenzin II receptora ili aliskirena povećava rizik od hipotenzije, hiperkalemije i smanjene bubrežne funkcije (uključujući akutno zatajenje bubrega).
Package leaflet: Information for the user Telmisartan Teva Pharma 20 mg Tablets
Uputa o lijeku: Informacije za korisnika Telmisartan Teva Pharma 20 mg tablete telmisartan
Each tablet contains 40 mg telmisartan
Svaka tableta sadrži 40 mg telmisartana.
Microcrystalline cellulose (Avicel PH 102) Sodium starch glycolate (Type A) Poloxamers
6.1 Popis pomoćnih tvari celuloza, mikrokristalična (Avicel PH 102) natrijev škroboglikolat (vrste A) poloksameri meglumin povidon (PVP K-30) sorbitol (E420) magnezijev stearat
Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased
Sniženi hemoglobin, povišene vrijednosti mokraćne kiseline u krvi, povišeni jetreni enzimi, povišena kreatin-fosfokinaza u krvi : za daljnje opise, molimo vidjeti pod “Opis odabranih nuspojava”.
Each tablet contains 80 mg telmisartan
Svaka tableta sadrži 80 mg telmisartana.
Each tablet contains 20 mg telmisartan
Svaka tableta sadrži 20 mg telmisartana.
Each Telmisartan Teva Pharma tablet contains 40 mg telmisartan.
Svaka Telmisartan Teva Pharma tableta sadrži 40 mg telmisartana.
Each Telmisartan Teva Pharma tablet contains 20 mg telmisartan.
Svaka Telmisartan Teva Pharma tableta sadrži 20 mg telmisartana.
Each Telmisartan Teva Pharma tablet contains 80 mg telmisartan.
Svaka Telmisartan Teva Pharma tableta sadrži 80 mg telmisartana.
Telmisartan Teva Pharma 40 mg tablets
Telmisartan Teva Pharma 40 mg tablete
Telmisartan Teva Pharma 80 mg tablets
Telmisartan Teva Pharma 80 mg tablete
Telmisartan Teva Pharma 20 mg tablets
Telmisartan Teva Pharma 20 mg tablete
EU/1/11/719/045 Cartons of 56x1 tablets in peelable perforated unit-dose aluminium-aluminium blisters
EU/1/11/719/065 28 tableta
Telmisartan Teva Pharma 20 mg tablets telmisartan
Telmisartan Teva Pharma 20 mg tablete telmisartan
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets
40x1 tableta 84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 30 tablets 28 tablets
84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta 30 tableta 28 tableta
Telmisartan Teva Pharma 80 mg tablets telmisartan
Telmisartan Teva Pharma 80 mg tablete telmisartan
Telmisartan Teva Pharma 80 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93".
Kako Telmisartan Teva Pharma izgleda i sadržaj pakiranja Telmisartan Teva Pharma 80 mg tablete su bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete je utisnut broj "93".
Telmisartan
Tahikardija
Telmisartan Teva Pharma 40 mg tablets telmisartan
Telmisartan Teva Pharma 40 mg tablete telmisartan
Telmisartan Teva Pharma 20 mg tablets are white to off white, oval shaped tablets; one side of the tablet is debossed with the number "93".
Kako Telmisartan Teva Pharma izgleda i sadržaj pakiranja Telmisartan Teva Pharma 20 mg tablete su bijele do gotovo bijele, ovalne tablete; na jednoj strani tablete je utisnut broj "93".
• type 2 diabetes mellitus with documented target organ damage
moždanog udara ili periferne arterijske bolesti), ili - dijabetes melitus tip 2 s dokazanim oštećenjem ciljnih organa.
14x1 tablets 28x1 tablets 30x1 tablets 40x1 tablets 56x1 tablets 60x1 tablets 84x1 tablets 90x1 tablets 98x1 tablets 100x1 tablets 28 tablets
84x1 tableta 90x1 tableta 98x1 tableta 100x1 tableta 28 tableta
The Marketing Authorisation Holder is: Teva B.V.
Ujedinjeno Kraljevstvo Pharmachemie B.V.
EU/1/11/719/041 14x1 tablets EU/1/11/719/042 28x1 tablets EU/1/11/719/043 30x1 tablets EU/1/11/719/044 40x1 tablets EU/1/11/719/045 56x1 tablets EU/1/11/719/046 60x1 tablets EU/1/11/719/047 84x1 tablets EU/1/11/719/048 90x1 tablets EU/1/11/719/049 98x1 tablets EU/1/11/719/050 100x1 tablets
EU/1/11/719/041 14x1 tableta EU/1/11/719/042 28x1 tableta EU/1/11/719/043 30x1 tableta EU/1/11/719/044 40x1 tableta EU/1/11/719/045 56x1 tableta EU/1/11/719/046 60x1 tableta EU/1/11/719/047 84x1 tableta EU/1/11/719/048 90x1 tableta EU/1/11/719/049 98x1 tableta EU/1/11/719/050 100x1 tableta
Name and address of the manufacturers responsible for batch release
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet Teva Pharmaceutical Works Private Limited Company